{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:35:46Z","timestamp":1788341746097,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.metabol.2024.155791","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T02:02:01Z","timestamp":1705284121000},"page":"155791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Effect of sodium-glucose cotransporter-2 inhibitors on continuous glucose monitoring metrics, as adjunctive to insulin in adults with type 1 diabetes mellitus: a meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"153","author":[{"given":"Djordje S.","family":"Popovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paschalis","family":"Karakasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theocharis","family":"Koufakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Fragakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Mitrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Gouveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Patoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2024.155791_bb0005","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.155791_bb0010","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/dme.12676","article-title":"Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison","volume":"32","author":"McKnight","year":"2015","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2024.155791_bb0015","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1055\/a-1392-0590","article-title":"Double diabetes: a growing problem requiring solutions","volume":"130","author":"Popovic","year":"2022","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.metabol.2024.155791_bb0020","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.155791_bb0025","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1002\/ehf2.13313","article-title":"SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis","volume":"8","author":"Yan","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.metabol.2024.155791_bb0030","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Tsutsui","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.155791_bb0035","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.155791_bb0040","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/dom.14060","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial","volume":"22","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2024.155791_bb0045","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE Trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.155791_bb0050","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 Study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.155791_bb0055","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 Study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.155791_bb0060","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.metabol.2024.155791_bb0065","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","article-title":"SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study","volume":"66","author":"Anson","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2024.155791_bb0070","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12325-019-0870-x","article-title":"Continuous glucose monitoring: a brief review for primary care practitioners","volume":"36","author":"Ajjan","year":"2019","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.metabol.2024.155791_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.17925\/USE.2012.08.01.27","article-title":"Continuous glucose monitoring versus self-monitoring of blood glucose in children with type 1 diabetes-are there pros and cons for both?","volume":"8","author":"Patton","year":"2012","journal-title":"US Endocrinol"},{"key":"10.1016\/j.metabol.2024.155791_bb0080","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/1932296815590154","article-title":"Time delay of CGM sensors: relevance, causes, and countermeasures","volume":"9","author":"Schmelzeisen-Redeker","year":"2015","journal-title":"J Diabetes Sci Technol"},{"issue":"S2","key":"10.1016\/j.metabol.2024.155791_bb0085","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1089\/dia.2017.0024","article-title":"Clinical use of continuous glucose monitoring in adults with type 2 diabetes","volume":"19","author":"Carlson","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.metabol.2024.155791_bb0090","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.diabet.2018.02.008","article-title":"The application of simple metrics in the assessment of glycaemic variability","volume":"44","author":"Monnier","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2024.155791_bb0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","article-title":"Continuous glucose monitoring and metrics for clinical trials: an international consensus statement","volume":"11","author":"Battelino","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2024.155791_bb0100","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training n.d. https:\/\/training.cochrane.org\/handbook\/current (accessed January 17, 2023)."},{"key":"10.1016\/j.metabol.2024.155791_bb0105","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2024.155791_bb0110","series-title":"citationchaser: an R package and Shiny app for forward and backward citations chasing in academic searching","author":"Haddaway","year":"2021"},{"key":"10.1016\/j.metabol.2024.155791_bb0115","series-title":"Deploying an interactive machine learning system in an Evidence-based Practice Center: Abstrackr. IHI\u201912 - Proc 2nd ACM SIGHIT Int Heal Informatics Symp","volume":"819-23","author":"Wallace","year":"2012"},{"key":"10.1016\/j.metabol.2024.155791_bb0120","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2024.155791_bb0125","unstructured":"Chapter 6: Choosing effect measures and computing estimates of effect | Cochrane Training n.d. https:\/\/training.cochrane.org\/handbook\/current\/chapter-06?fbclid=IwAR0l8kw8aAEkBECwmPHnxYYiEWvLDM9XXzoMCmhG0pkx1tRl5qB1ASs9xWY#section-6-5-2-2 (accessed August 20, 2023)."},{"key":"10.1016\/j.metabol.2024.155791_bb0130","unstructured":"GRADEpro n.d. https:\/\/www.gradepro.org\/ (accessed March 1, 2023)."},{"key":"10.1016\/j.metabol.2024.155791_bb0135","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41591-022-01805-3","article-title":"Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2\u00d72 factorial randomized crossover trial","volume":"28","author":"Haidar","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2024.155791_bb0140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/dia.2021.0542","article-title":"Automated insulin delivery with SGLT2i combination therapy in type 1 diabetes","volume":"24","author":"Garcia-Tirado","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.metabol.2024.155791_bb0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/dia.2020.0079","article-title":"Effects of sotagliflozin combined with intensive insulin therapy in young adults with poorly controlled type 1 diabetes: the JDRF Sotagliflozin Study","volume":"23","author":"Bode","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.metabol.2024.155791_bb0150","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2337\/dc18-2149","article-title":"Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the inTandem program","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.155791_bb0155","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.155791_bb0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2337\/dc16-1353","article-title":"The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes","volume":"40","author":"Rodbard","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.155791_bb0165","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes","volume":"38","author":"Sands","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.155791_bb0170","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/M22-3078","article-title":"Prevalence and management of obesity in U.S. adults with type 1 diabetes","volume":"176","author":"Fang","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2024.155791_bb0175","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(21)00246-1","article-title":"Obesity in people living with type 1 diabetes","volume":"9","author":"Van der Schueren","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2024.155791_bb0180","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1210\/clinem\/dgab927","article-title":"Obesity and chronic kidney disease in US adults with type 1 and type 2 diabetes mellitus","volume":"107","author":"Wallace","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.155791_bb0185","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/1574884713666180807150509","article-title":"SGLT-2 inhibitors in type 1 diabetes mellitus: a comprehensive review of the literature","volume":"13","author":"Patoulias","year":"2018","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.metabol.2024.155791_bb0190","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/jdi.13387","article-title":"Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"12","author":"Zou","year":"2021","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.metabol.2024.155791_bb0195","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/1753-0407.12890","article-title":"Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: a meta-analysis of randomized controlled trials","volume":"11","author":"Li","year":"2019","journal-title":"J Diabetes"},{"key":"10.1016\/j.metabol.2024.155791_bb0200","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.2337\/dc15-1188","article-title":"Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis","volume":"38","author":"Gorst","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2024.155791_bb0205","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/jdi.12840","article-title":"Glycemic extremes are related to cognitive dysfunction in children with type 1 diabetes: a meta-analysis","volume":"9","author":"He","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.metabol.2024.155791_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003461","article-title":"Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: a meta-analysis and meta-regression","volume":"17","author":"Musso","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.metabol.2024.155791_bb0215","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1570161121666230817105105","article-title":"The recent trends in all-cause and cardiovascular mortality among people with type 1 diabetes mellitus-success is still far away, and we must do better!","volume":"21","author":"Popovic","year":"2023","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.metabol.2024.155791_bb0220","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/dom.13811","article-title":"Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: the STOP DKA protocol","volume":"21","author":"Goldenberg","year":"2019","journal-title":"Diabetes Obes Metab"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524000179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524000179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:34:11Z","timestamp":1758429251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524000179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":44,"alternative-id":["S0026049524000179"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.155791","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of sodium-glucose cotransporter-2 inhibitors on continuous glucose monitoring metrics, as adjunctive to insulin in adults with type 1 diabetes mellitus: a meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.155791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155791"}}